Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Intangibles (2020 - 2025)

Bioventus (BVS) has disclosed Intangibles for 6 consecutive years, with $368.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Intangibles fell 8.97% year-over-year to $368.4 million, compared with a TTM value of $368.4 million through Dec 2025, down 8.97%, and an annual FY2025 reading of $368.4 million, down 8.97% over the prior year.
  • Intangibles was $368.4 million for Q4 2025 at Bioventus, down from $377.4 million in the prior quarter.
  • Across five years, Intangibles topped out at $1.1 billion in Q4 2022 and bottomed at $257.8 million in Q3 2021.
  • Average Intangibles over 5 years is $505.2 million, with a median of $476.5 million recorded in 2023.
  • The sharpest move saw Intangibles soared 262.74% in 2021, then tumbled 53.27% in 2023.
  • Year by year, Intangibles stood at $695.2 million in 2021, then decreased by 7.96% to $639.9 million in 2022, then fell by 24.62% to $482.4 million in 2023, then fell by 16.09% to $404.7 million in 2024, then dropped by 8.97% to $368.4 million in 2025.
  • Business Quant data shows Intangibles for BVS at $368.4 million in Q4 2025, $377.4 million in Q3 2025, and $387.0 million in Q2 2025.